Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 91 | 1 | 95 | +5 |
| Shares | 56.6M | 100 | 56.6M | +1.80K (0.0%) |
| Value | $324.6M | $1.00K | $201.9M | −$122.8M (−37.8%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Colonial River Wealth Management, LLC | 66,200 | $218.0K | 0.15% |
| Prudential Financial Inc | 50,510 | $180.0K | 0.00% |
| SG Americas Securities, LLC | 24,478 | $87.0K | 0.00% |
| Susquehanna International Group, LLP | 23,523 | $84.0K | 0.00% |
| LPL Financial LLC | 21,326 | $76.0K | 0.00% |
| Raymond James Financial Services Advisors, Inc. | 15,749 | $56.0K | 0.00% |
| B. Riley Wealth Management, Inc. | 14,000 | $50.0K | 0.00% |
| Ameriprise Financial Inc | 13,770 | $49.0K | 0.00% |
| DCF Advisers, LLC | 12,149 | $43.0K | 0.02% |
| LMR Partners LLP | 10,000 | $36.0K | 0.00% |
| Koshinski Asset Management, Inc. | 3,200 | $11.4K | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 2,433 | $9.00K | 0.00% |
| The PNC Financial Services Group, Inc. | 302 | $1.00K | 0.00% |
| Parallel Advisors, LLC | 222 | $1.00K | 0.00% |
| Berman Capital Advisors, LLC | 312 | $1.00K | 0.00% |
| Lindbrook Capital, LLC | 194 | $1.00K | 0.00% |
| Ellevest, Inc. | 67 | $0 | 0.00% |
Sold out (12)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Parian Global Management LP | 1,045,968 | $6.00M |
| Maven Securities LTD | 476,682 | $2.73M |
| Private Wealth Partners, LLC | 150,000 | $861.0K |
| Bridgeway Capital Management, LLC | 105,300 | $604.0K |
| Gsa Capital Partners LLP | 37,641 | $216.0K |
| MetLife Investment Management | 28,960 | $166.2K |
| Metropolitan Life Insurance Co | 23,233 | $133.4K |
| Pinz Capital Management, LP | 21,700 | $125.0K |
| ProShare Advisors LLC | 18,383 | $106.0K |
| Cubist Systematic Strategies, LLC | 13,391 | $77.0K |
| Signaturefd, LLC | 128 | $1.00K |
| Iron Horse Wealth Management, LLC | 5 | $0 |
Not filed for Q3 2021 yet (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| CWM, LLC | 100 | $1.00K |